As a Novel Prognostic Marker, Cysteine/histidine-rich 1 (CYHR1) is a Therapeutic Target in Patients with Esophageal Squamous Cell Carcinoma

Ryosuke Desaki, Genta Sawada, Hiroshi Okumura, Ryuji Ikeda, Kan Tanabe, Hisateru Komatsu, Koshi Mimori, Masaki Mori, Yoshiaki Kita, Yasuto Uchikado, Takaaki Arigami, Yoshikazu Uenosono, Tetsuhiro Owaki, Sumiya Ishigami, Shoji Natsugoe

Research output: Contribution to journalArticle

Abstract

Background: Cysteine/histidine-rich 1 (CYHR1) was first discovered in a yeast two-hybrid screen with murine galectin-3, and no previous reports have described a relationship between the CYHR1 gene and human cancer. The current study evaluated the role and significance of CYHR1 in esophageal cancer. Methods: The human esophageal squamous cell carcinoma (ESCC) cell line TE-8 and the CYHR1 knock-down cell line TE-8/small interfering (si)-CYHR1 were used for in vitro and in vivo assays. For clinical study, ESCC tissues (n = 104) were used. Results: Compared with parental cells, TE-8/si-CYHR1 cells had suppressed proliferation and invasion activities. In the in vivo assay, the tumors from TE-8 cells treated with si-CYHR1 had abrogated tumorigenicity. In the clinical study, the expression of CYHR1 mRNA was associated with lymph node metastasis and stage and shown to be an independent prognostic factor. Conclusions: As the findings show, CYHR1 may represent not only a valuable prognostic marker but also a therapeutic target for ESCC patients.

Original languageEnglish
Pages (from-to)586-593
Number of pages8
JournalAnnals of Surgical Oncology
Volume24
Issue number2
DOIs
Publication statusPublished - Feb 1 2017

All Science Journal Classification (ASJC) codes

  • Surgery
  • Oncology

Fingerprint Dive into the research topics of 'As a Novel Prognostic Marker, Cysteine/histidine-rich 1 (CYHR1) is a Therapeutic Target in Patients with Esophageal Squamous Cell Carcinoma'. Together they form a unique fingerprint.

  • Cite this

    Desaki, R., Sawada, G., Okumura, H., Ikeda, R., Tanabe, K., Komatsu, H., Mimori, K., Mori, M., Kita, Y., Uchikado, Y., Arigami, T., Uenosono, Y., Owaki, T., Ishigami, S., & Natsugoe, S. (2017). As a Novel Prognostic Marker, Cysteine/histidine-rich 1 (CYHR1) is a Therapeutic Target in Patients with Esophageal Squamous Cell Carcinoma. Annals of Surgical Oncology, 24(2), 586-593. https://doi.org/10.1245/s10434-015-5031-0